Therapeutic peptides for cancer therapy. Part I - Peptide inhibitors of signal transduction cascades

Expert Opinion on Drug Delivery

Volumn 6, Issue 10, 2009, Pages 1033-1047

  Bidwell III, Gene L ^a   Raucher, Drazen ^a  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

c Myc; Drug delivery; Jun N terminal kinase; NF B; p53; Ras; Therapeutic peptide

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LZ PENETRATIN FUSION PROTEIN; LZ POLYARGININE FUSION PROTEIN; MAX PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NBD PENETRATIN FUSION PROTEIN; NBD PTD 5 FUSION PROTEIN; PENETRATIN PEPTIDE 46 FUSION PROTEIN; PEPTIDE DERIVATIVE; PROTEIN C JUN; PROTEIN CDB3; PROTEIN H1 S6A PENETRATIN FUSION PROTEIN; PROTEIN JNK 1; PROTEIN MDM2; PROTEIN NBD; PROTEIN P53; PROTEIN PNC 27; PROTEIN PNC 28; PROTEIN SN50; PROTEIN SN52; STAT1 PROTEIN; TAT JIP FUSION PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; CANCER INHIBITION; CANCER THERAPY; CONTINUOUS INFUSION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; HUMAN; LIVER METASTASIS; MELANOMA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; NF-KAPPA B; PEPTIDES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349388055     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903143745     Document Type: Review

References (120)

1. Talmadge JE. Pharmacodynamic aspects of peptide administration biological response modifiers. Adv Drug Deliv Rev 1998;33(3):241-52 • This work describes the current limitations of in vivo peptide delivery.
2. Lipka E, Crison J, Amidon GL. Transmembrane transport of peptide type compounds: prospects for oral delivery. J Control Release 1996;39(2-3):121-129 (Pubitemid 26194211)
3. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;276(8):5836-5840 (Pubitemid 37385738)
4. Massodi I, Bidwell GL 3rd, Raucher D. Evaluation of cell penetrating peptides fused to elastin-like polypeptide for drug delivery. J Control Release 2005;108(2-3):396-408 (Pubitemid 41608671)
5. Vives E, Richard JP, Rispal C, etal. TAT peptide internalization: seeking the mechanism of entry. Curr Protein Pept Sci 2003;4(2):125-132
6. Vives E. Cellular uptake [correction of utake] of the Tat peptide: an endocytosis mechanism following ionic interactions. J Mol Recognit 2003;16(5):265-271 (Pubitemid 37231695)
7. Raucher D, Massodi I, Bidwell GL. Thermally targeted delivery of chemotherapeutics and anti-cancer peptides by elastin-like polypeptide. Expert Opin Drug Deliv 2008;5(3):353-369
8. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008;60(4-5):548-558 (Pubitemid 351215572)
9. Derossi D, Joliot AH, Chassaing G, et al. The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994;269(14):10444-10450 (Pubitemid 24198241)
10. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272(25):16010-16017 (Pubitemid 27265584)
11. Lin YZ, Yao SY, Veach RA, etal. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995;270(24):14255-14258
12. Sadler K, Eom KD, Yang JL, et al. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 2002;41(48):14150- 14157 (Pubitemid 35403333)
13. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 1998;8(2):84-87 (Pubitemid 28056816)
14. Lundberg P, Langel U. A brief introduction to cell-penetrating peptides. J Mol Recognit 2003;16(5):227-233
15. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 2005;57(4):637-651 (Pubitemid 40255564)
16. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827
17. Feig LA. The many roads that lead to Ras. Science 1993;260(5109):767-768 (Pubitemid 23167604)
18. Adari H, Lowy DR, Willumsen BM, et al. Guanosine triphosphatase activating protein (GAP) interacts with the p21 ras effector binding domain. Science 1988;240(4851):518-521
19. Moodie SA, Willumsen BM, Weber MJ, et al. Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 1993;260(5114):1658-1661 (Pubitemid 23247150)
20. Barbacid M. Involvement of ras oncogenes in the initiation of carcinogen-induced tumors. Princess Takamatsu Symp 1986;17:43-53
21. Chung DL, Brandt-Rauf P, Murphy RB, et al. A peptide from the GAP-binding domain of the ras-p21 protein and azatyrosine block ras-induced maturation of Xenopus oocytes. Anticancer Res 1991;11(4):1373-1378 •• This paper describes one of the first TPs developed, aimed at inhibiting Ras signaling.
22. Haspel J, Dykes DC, Friedman FK, et al. Inhibition of ras-oncogene-encoded p21 protein-induced maturation of oocytes by p21 peptide sequences predicted to be effector domain sites by molecular modeling. Med Sci Res 1992;20:809-811
23. Adler V, Pincus MR, Brandt-Rauf PW, et al. Complexes of p21RAS with JUN N-terminal kinase and JUN proteins.Proc Natl Acad Sci USA 1995;92(23):10585- 10589
24. Chie L, Chen JM, Friedman FK, et al. Identification of the site of inhibition of oncogenic ras-p21-induced signal transduction by a peptide from a ras effector domain. J Protein Chem 1999;18(8):881-884 (Pubitemid 30323929)
25. Barnard D, Sun H, Baker L, etal. Invitro inhibition of Ras-Raf association by short peptides. Biochem Biophys Res Commun 1998;247(1):176-180
26. Kanovsky M, Michl J, Botzolaki G, et al. Peptides designed from molecular modeling studies of the ras-p21 protein induce phenotypic reversion of a pancreatic carcinoma cell line but have no effect on normal pancreatic acinar cell growth. Cancer Chemother Pharmacol 2003;52(3):202-208 (Pubitemid 37204533)
27. Adler V, Bowne W, Kamran I, etal. Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells. Cancer Chemother Pharmacol 2008;62(3):491-498
28. Chen JM, Friedman FK, Hyde MJ, et al. Molecular dynamics analysis of the structures of ras-guanine nucleotide exchange protein (SOS) bound to wild-type and oncogenic ras-p21. Identification of effector domains of SOS. J Protein Chem 1999;18(8):867-874
29. Chie L, Chen JM, Friedman FK, et al. Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the guanine-nucleotide exchange protein, SOS, identified from molecular dynamics calculations. Selective inhibition of oncogenic ras-p21. J Protein Chem 1999;18(8):875-879 (Pubitemid 30323928)
30. Chen JM, Friedman FK, Brandt-Rauf PW, et al. Comparison of the average structures, from molecular dynamics, of complexes of GTPase activating protein (GAP) with oncogenic and wild-type ras-p21: identification of potential effector domains. J Protein Chem 2002;21(5):349-359
31. Friedman FK, Chie L, Chung D, et al. Inhibition of ras-induced oocyte maturation by peptides from ras-p21 and GTPase activating protein (GAP) identified as being effector domains from molecular dynamics calculations. J Protein Chem 2002;21(5):361-366 (Pubitemid 34913071)
32. Chen JM, Monaco R, Manolatos S, et al. Molecular dynamics on complexes of ras-p21 and its inhibitor protein, rap-1A, bound to the ras-binding domain of the raf-p74 protein: identification of effector domains in the raf protein. J Protein Chem 1997;16(6):619-629 (Pubitemid 27328511)
33. Chung D, Amar S, Glozman A, et al. Inhibition of oncogenic and activated wild-type ras-p21 protein-induced oocyte maturation by peptides from the ras-binding domain of the raf-p74 protein, identified from molecular dynamics calculations. J Protein Chem 1997;16(6):631-635 (Pubitemid 27328512)
34. Clark GJ, Drugan JK, Terrell RS, et al. Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function. Proc Natl Acad Sci USA 1996;93(4):1577-1581
35. Rojas M, Yao S, Lin YZ. Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor. J Biol Chem 1996;271(44):27456-27461 (Pubitemid 26367305)
36. Buday L, Downward J. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993;73(3):611-620
37. Rojas M, Yao S, Donahue JP, etal. An alternative to phosphotyrosine- containing motifs for binding to an SH2 domain. Biochem Biophys Res Commun 1997;234(3):675-680
38. Qian Y, Blaskovich MA, Saleem M, et al. Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase. J Biol Chem 1994;269(17):12410-12413 (Pubitemid 24982266)
39. Brown MS, Goldstein JL, Paris KJ, et al. Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine- containing tetrapeptides restores farnesylation. Proc Natl Acad Sci USA 1992;89(17):8313-8316
40. Reiss Y, Goldstein JL, Seabra MC, et al. Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 1990;62(1):81-88 (Pubitemid 20216288)
41. Ohkanda J, Knowles DB, Blaskovich MA, et al. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr Top Med Chem 2002;2(3):303-323
42. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6(7):541-555
43. Sousa SF, Fernandes PA, Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem 2008;15(15):1478-1492
44. Cobb MH, Hepler JE, Cheng M, etal. The mitogen-activated protein kinases, ERK1 and ERK2. Semin Cancer Biol 1994;5(4):261-268
45. Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 1996;8(2):205-215 (Pubitemid 26109094)
46. Adler V, Qu Y, Smith SJ, etal. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway. Biochemistry 2005;44(32):10784-10795
47. Kelemen BR, Hsiao K, Goueli SA. Selective invivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides. J Biol Chem 2002;277(10):8741-8748 (Pubitemid 34968342)
48. Adler V, Yin Z, Fuchs SY, etal. Regulation of JNK signaling by GSTp. Embo J 1999;18(5):1321-1334
49. Adler V, Pincus MR. Effector peptides from glutathione-S-transferase-pi affect the activation of jun by jun-N-terminal kinase. Ann Clin Lab Sci 2004;34(1):35-46 (Pubitemid 38280302)
50. Chie L, Adler V, Friedman FK, et al. An effector peptide from glutathione-S-transferase-pi strongly and selectively blocks mitotic signaling by oncogenic ras-p21. Protein J 2004;23(3):235-238 (Pubitemid 41399332)
51. Barr RK, Kendrick TS, Bogoyevitch MA. Identification of the critical features of a small peptide inhibitor of JNK activity. J Biol Chem 2002;277(13):10987-97 • This paper describes a peptide-based strategy for inhibiting the JNK signaling cascade.
52. Bonny C, Oberson A, Negri S, et al. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 2001;50(1):77-82 (Pubitemid 32047984)
53. Borsello T, Clarke PG, Hirt L, etal. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat Med 2003;9(9):1180-1186
54. Bogoyevitch MA. Therapeutic promise of JNK ATP-noncompetitive inhibitors. Trends Mol Med 2005;11(5):232-239
55. Bogoyevitch MA, Barr RK, Ketterman AJ. Peptide inhibitors of protein kinases-discovery, characterisation and use. Biochim Biophys Acta 2005;1754(1-2):79-99 •• This review covers the development of kinase-inhibiting peptides, including some less extensively studied peptides not covered in this review owing to lack of space.
56. Bogoyevitch MA, Arthur PG. Inhibitors of c-Jun N-terminal kinases: JuNK no more? Biochim Biophys Acta 2008;1784(1):76-93
57. Gao YJ, Cheng JK, Zeng Q, etal. Selective inhibition of JNK with a peptide inhibitor attenuates pain hypersensitivity and tumor growth in a mouse skin cancer pain model. Exp Neurol 2009. In press • This paper describes an in vivo application of the NBD peptide for treatment of melanoma.
58. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008;132(3):344-362
59. May MJ, D'Acquisto F, Madge LA, et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000;289(5484):1550-4 This paper is one of the first descriptions of an NF-kappaB modulating peptide, and the peptide described here was later used effectively in animal models of many diseases with an inflammatory component, and in an animal model of melanoma. (Pubitemid 30677473)
60. Dasgupta S, Jana M, Zhou Y, et al. Antineuroinflammatory effect of NF-kappaB essential modifier-binding domain peptides in the adoptive transfer model of experimental allergic encephalomyelitis. J Immunol 2004;173(2):1344- 1354 (Pubitemid 38924314)
61. di Meglio P, Ianaro A, Ghosh S. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 2005;52(3):951-958 (Pubitemid 40365119)
62. Tas SW, Vervoordeldonk MJ, Hajji N, et al. Local treatment with the selective IkappaB kinase beta inhibitor NEMO-binding domain peptide ameliorates synovial inflammation. Arthritis Res Ther 2006;8(4):R86
63. Ghosh A, Roy A, Liu X, etal. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2007;104(47):18754-18759
64. Rehman KK, Bertera S, Bottino R, et al. Protection of islets by in situ peptide-mediated transduction of the Ikappa B kinase inhibitor Nemo-binding domain peptide. J Biol Chem 2003;278(11):9862-9868 (Pubitemid 36800489)
65. Thomas RP, Farrow BJ, Kim S, et al. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery 2002;132(2):127-134 (Pubitemid 35024752)
66. Biswas DK, Shi Q, Baily S, et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004;101(27):10137-10142 (Pubitemid 38891208)
67. Tapia MA, Gonzalez-Navarrete I, Dalmases A, etal. Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 2007;6(18):2284-2292
68. Ianaro A, Tersigni M, Belardo G, et al. NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Lett 2009;274(2):331-336
69. Agou F, Traincard F, Vinolo E, etal. The trimerization domain of NEMO is composed of the interacting C-terminal CC2 and LZ coiled-coil subdomains. J Biol Chem 2004;279(27):27861-27869 (Pubitemid 38900054)
70. Agou F, Courtois G, Chiaravalli J, et al. Inhibition of NF-kappa B activation by peptides targeting NF-kappa B essential modulator (nemo) oligomerization. J Biol Chem 2004;279(52):54248-54257 (Pubitemid 40053162)
71. Carvalho G, Fabre C, Braun T, et al. Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 2007;26(16):2299-2307 (Pubitemid 46572822)
72. Torgerson TR, Colosia AD, Donahue JP, et al. Regulation of NF-kappa B, AP-1, NFAT, and STAT1 nuclear import in T lymphocytes by noninvasive delivery of peptide carrying the nuclear localization sequence of NF-kappa B p50. J Immunol 1998;161(11):6084-92 • This paper describes an NLS peptide capable of inhibiting nuclear localization of several important proteins, and this peptide has also been applied successfully in several animal models of inflammatory diseases.
73. Letoha T, Somlai C, Takacs T, etal. A nuclear import inhibitory peptide ameliorates the severity of cholecystokinin-induced acute pancreatitis. World J Gastroenterol 2005;11(7):990-999 (Pubitemid 40347751)
74. Saika S, Miyamoto T, Yamanaka O, et al. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factor-kappaB, in treatment of corneal alkali burns in mice. Am J Pathol 2005;166(5):1393-1403 (Pubitemid 40586510)
75. Gonzalez-Ramos R, Van Langendonckt A, Defrere S, etal. Agents blocking the nuclear factor-kappaB pathway are effective inhibitors of endometriosis in an invivo experimental model.Gynecol Obstet Invest 2008;65(3):174-186
76. Poulaki V, Mitsiades CS, Joussen AM, et al. Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.Am J Pathol 2002;161(6):2229-2240
77. Starenki D, Namba H, Saenko V, et al. Inhibition of nuclear factor-kappaB cascade potentiates the effect of a combination treatment of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2004;89(1):410-418 (Pubitemid 38183911)
78. Xu Y, Fang F, St Clair DK, etal. SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 2008;7(8):2367-2376
79. Yan Liu X, Robinson D, Veach RA, et al. Peptide-directed suppression of a pro-inflammatory cytokine response. J Biol Chem 2000;275(22):16774-16778 (Pubitemid 30398910)
80. Fujihara SM, Cleaveland JS, Grosmaire LS, et al. A D-amino acid peptide inhibitor of NF-kappa B nuclear localization is efficacious in models of inflammatory disease. J Immunol 2000;165(2):1004-1012
81. Yaron A, Gonen H, Alkalay I, et al. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. Embo J 1997;16(21):6486-6494 (Pubitemid 27483274)
82. Takada Y, Singh S, Aggarwal BB. Identification of a p65 peptide that selectively inhibits NF-kappa B activation induced by various inflammatory stimuli and its role in down-regulation of NF-kappaB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 2004;279(15):15096-15104 (Pubitemid 38618904)
83. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995;83(2):237-45 • This paper describes the first peptides capable of restoring p53 function.
84. Selivanova G, Iotsova V, Okan I, et al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med 1997;3(6):632-638 (Pubitemid 27264972)
85. Selivanova G, Ryabchenko L, Jansson E, et al. Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol 1999;19(5):3395-3402 (Pubitemid 29193799)
86. Kim AL, Raffo AJ, Brandt-Rauf PW, et al. Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J Biol Chem 1999;274(49):34924-34931
87. Li Y, Rosal RV, Brandt-Rauf PW, et al. Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide. Biochem Biophys Res Commun 2002;298(3):439-449 (Pubitemid 35333726)
88. Li Y, Mao Y, Rosal RV, etal. Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells. Int J Cancer 2005;115(1):55-64 (Pubitemid 40559668)
89. Friedler A, Hansson LO, Veprintsev DB, et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 2002;99(2):937-942 (Pubitemid 34106614)
90. Issaeva N, Friedler A, Bozko P, et al. Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 2003;100(23):13303-13307 (Pubitemid 37444737)
91. Bottger A, Bottger V, Sparks A, et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997;7(11):860-9 This paper describes a strategy for increasing peptide stability by expressing it as part of a mini protein. (Pubitemid 27493125)
92. Wasylyk C, Salvi R, Argentini M, etal. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999;18(11):1921-1934 (Pubitemid 29150079)
93. Kanovsky M, Raffo A, Drew L, et al. Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc Natl Acad Sci USA 2001;98(22):12438-12443 (Pubitemid 33019964)
94. Do TN, Rosal RV, Drew L, et al. Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene 2003;22(10):1431-1444 (Pubitemid 36401512)
95. Bowne WB, Sookraj KA, Vishnevetsky M, et al. The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Ann Surg Oncol 2008;15(12):3588-3600
96. Michl J, Scharf B, Schmidt A, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth invivo. Int J Cancer 2006;119(7):1577-85 This paper describes the application of a p53-derived peptide in a mouse xenograft model, and this work is some of the most advanced preclinical testing published with a TP in a cancer model. (Pubitemid 44258763)
97. Harbour JW, Worley L, Ma D, et al. Transducible peptide therapy for uveal melanoma and retinoblastoma.Arch Ophthalmol 2002;120(10):1341-1346
98. Midgley CA, Desterro JM, Saville MK, et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination invitro and can activate p53 invivo. Oncogene 2000;19(19):2312-2323
99. Karlsson GB, Jensen A, Stevenson LF, et al. Activation of p53 by scaffold-stabilised expression of Mdm2-binding peptides: visualisation of reporter gene induction at the single-cell level. Br J Cancer 2004;91(8):1488-1494 (Pubitemid 39486353)
100. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2(10):764-776 (Pubitemid 37328911)
101. Blackwood EM, Luscher B, Eisenman RN. Myc and Max associate invivo. Genes Dev 1992;6(1):71-80
102. Draeger LJ, Mullen GP. Interaction of the bHLH-zip domain of c-Myc with H1-type peptides. Characterization of helicity in the H1 peptides by NMR. J Biol Chem 1994;269(3):1785-93 • This paper introduces the only peptide described so far capable of inhbiting c-Myc function.
103. Giorello L, Clerico L, Pescarolo MP, et al. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence. Cancer Res 1998;58(16):3654-3659 (Pubitemid 28376565)
104. Pescarolo MP, Bagnasco L, Malacarne D, et al. A retro-inverso peptide homologous to helix 1 of c-Myc is a potent and specific inhibitor of proliferation in different cellular systems. Faseb J 2001;15(1):31-33
105. Nieddu E, Melchiori A, Pescarolo MP, et al. Sequence specific peptidomimetic molecules inhibitors of a protein-protein interaction at the helix 1 level of c-Myc. Faseb J 2005;19(6):632-634 (Pubitemid 40471268)
106. Bagnasco L, Tortolina L, Biasotti B, et al. Inhibition of a protein-protein interaction between INI1 and c-Myc by small peptidomimetic molecules inspired by Helix-1 of c-Myc: identification of a new target of potential antineoplastic interest. Faseb J 2007;21(4):1256-1263 (Pubitemid 46495714)
107. Urry DW, Luan C-H, Parker TM, et al. Temperature of polypeptide inverse temperature transition depends on mean residue hydrophobicity. J Am Chem Soc 1991;113:4346-4348
108. Meyer DE, Kong GA, Dewhirst MW, et al. Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res 2001;61(4):1548-1554
109. Liu W, Dreher MR, Furgeson DY, et al. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release 2006;116(2):170-178 (Pubitemid 44854277)
110. Dreher MR, Liu W, Michelich CR, et al. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res 2007;67(9):4418-4424 (Pubitemid 46815091)
111. Bidwell GL 3rd, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther 2005;4(7):1076-85 •• This work demonstrates the potential of using a targeted carrier for delivery of a TP.
112. Bidwell GL 3rd, Raucher D. Enhancing the antiproliferative effect of topoisomerase II inhibitors using a polypeptide inhibitor of c-Myc. Biochem Pharmacol 2006;71(3):248-256
113. Bidwell GL 3rd, Davis AN, Raucher D. Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. J Control Release 2009;135(1):2-10
114. Takakura Y, Fujita T, Hashida M, et al. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: biopharmaceutical and pharmacological properties. J Pharm Sci 1989;78(3):219-222 (Pubitemid 19079846)
115. Dreher MR, Liu W, Michelich CR, et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006;98(5):335-344 (Pubitemid 43338213)
116. Torchilin VP, Lukyanov AN. Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 2003;8(6):259-266 (Pubitemid 36293499)
117. Kratz F, Abu Ajaj K, Warnecke A. Anticancer carrier-linked prodrugs in clinical trials. Expert Opin Investig Drugs 2007;16(7):1037-1058 (Pubitemid 47074159)
118. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6(1):1-16
119. Soppimath KS, Aminabhavi TM, Dave AM, etal. Stimulus-responsive 'smart' hydrogels as novel drug delivery systems. Drug Dev Ind Pharm 2002;28(8):957-974
120. Yuan Q, Venkatasubramanian R, Hein S, et al. A stimulus-responsive magnetic nanoparticle drug carrier: magnetite encapsulated by chitosan-grafted-copolymer. Acta Biomater 2008;4(4):1024-1037